The purpose of this study is to evaluate the safety and efficacy of treatment with TAK-875 in diabetic patients.
Inclusion Criteria:
Exclusion Criteria:
Niihama-shi, Ehime, Japan
Onga-gun, Fukuoka, Japan
Yukuhashi-shi, Fukuoka, Japan
Chitose-shi, Hokkaido, Japan
Koga-shi, Ibaragi, Japan
Ushiku-shi, Ibaragi, Japan
Chigasaki-shi, Kanagawa, Japan
Kamakura-shi, Kanagawa, Japan
Minamata-shi, Kumamoto, Japan
Yatsushiro-shi, Kumamoto, Japan
Sasebo-shi, Nagasaki, Japan
Okinawa-shi, Okinawa, Japan
Izumi-shi, Osaka, Japan
Suita-shi, Osaka, Japan
Fujimi-shi, Saitama, Japan
Shimotsuga-gun, Tochigi, Japan
Komatsushima-shi, Tokushima, Japan
Bunkyo-ku, Tokyo, Japan
Chiyoda-ku, Tokyo, Japan
Mitaka-shi, Tokyo, Japan
Shibuya-ku, Tokyo, Japan
Shinjuku-ku, Tokyo, Japan
Toshima-ku, Tokyo, Japan
Shunan-shi, Yamaguchi, Japan
Ube-shi, Yamaguchi, Japan